- AbCellera announced on Thursday Feb 10th a supply deal with the US government and Lilly for Bebtelovimab, the AbCellera developed pan COVID variant antibody treatment.
- The supply deal includes an initial 600,000 doses valued at $720 million with an option for an additional 500,000 doses.
- AbCellera shares have fallen off of a cliff as of late and this news, along with hopefully formal EUA approval for Bebtelovimab should place a solid floor under shares.
For further details see:
AbCellera Biologics: Bebtelovimab Supply Deal Provides A Much Needed Shot In The Arm